The yeast oligonucleotide array is constructed using the S. cerevisiae Genome Oligo Set ™ (Operon Technologies, CA, USA) composed of 6240 optimized oligonucleotides (70mers) each representing one yeast gene.

The primary objective of this trial is to determine toxicity and feasibility of treatment of patients with advanced melanoma with DC vaccine and adoptive transfer.

Monocyte-derived DCs are added at a final concentration of 5x105 cells/ml into 96-well plates.

Serial diluition of yeast cells and preparations are added to the MoDCs.

The cells are collected and the pellets are resuspended in 3.6 ml AE Buffer (AE=50mM NaAcetate pH 5.2, 10mM EDTA) and then transferred in 15 ml tubes wit 200 µl 10% SDS (w/v). 2 ml of preheated acid phenol (pH 4.3) are added and the falcon is mixed by vortex.

To assess the importance of ROS production in DC killing ability, DPI (10 microM) is added 30 minutes before stimulation.